Company profile
CUMBERLAND PHARMACEUTICALS INC
NASDAQ:CPIXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Amoxicillin | approved | — | 14 | approved |
| Clarithromycin | approved | — | 11 | approved |
| CONIVAPTAN HYDROCHLORIDE | approved | — | 6 | approved |
| Omeprazole | approved | — | 19 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (47)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01887470 | phase2 | completed | 2013-07-01 | 2013-10-01 | Cumberland Pharmaceuticals | 2 Regimens of Lactulose for Colonoscopy Preparation in Adults |
| NCT02208063 | phase3 | terminated | 2014-12-01 | 2018-04-12 | Cumberland Pharmaceuticals | A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial |
| NCT01650519 | phase4 | completed | 2012-09-01 | 2012-12-01 | Cumberland Pharmaceuticals | A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery |
| NCT00712543 | phase4 | completed | 2009-06-01 | 2009-09-01 | Cumberland Pharmaceuticals | A Preference Study Comparing Kristalose® and Liquid Lactulose |
| NCT00225706 | phase3 | completed | 2005-10-01 | 2007-08-01 | Cumberland Pharmaceuticals | A Study of Caldolor in Hospitalized Febrile Pediatric Patients |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 022016 | NDA | CUMBERLAND PHARMS | ||||
Loading… | ||||||
| NDA 050824 | NDA | CUMBERLAND PHARMACEUTICALS INC | ||||
Loading… | ||||||